Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2004 4
2005 1
2006 2
2007 1
2008 3
2009 6
2010 4
2011 6
2012 5
2013 8
2014 6
2015 7
2016 6
2017 11
2018 5
2019 3
2020 4
2021 7
2022 9
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Johnson PJ, et al. Among authors: inarrairaegui m. J Clin Oncol. 2015 Feb 20;33(6):550-8. doi: 10.1200/JCO.2014.57.9151. Epub 2014 Dec 15. J Clin Oncol. 2015. PMID: 25512453 Free PMC article.
[Hepatocellular carcinoma].
Iñarrairaegui M. Iñarrairaegui M. An Sist Sanit Navar. 2016 Mayo-Agosto;39(2):179-80. doi: 10.23938/ASSN.0275. An Sist Sanit Navar. 2016. PMID: 27599946 Free article. Spanish. No abstract available.
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q, Klein C, Caruso S, Maille P, Allende DS, Mínguez B, Iavarone M, Ningarhari M, Casadei-Gardini A, Pedica F, Rimini M, Perbellini R, Boulagnon-Rombi C, Heurgué A, Maggioni M, Rela M, Vij M, Baulande S, Legoix P, Lameiras S; HCC-AI study group; Bruges L, Gnemmi V, Nault JC, Campani C, Rhee H, Park YN, Iñarrairaegui M, Garcia-Porrero G, Argemi J, Sangro B, D'Alessio A, Scheiner B, Pinato DJ, Pinter M, Paradis V, Beaufrère A, Peter S, Rimassa L, Di Tommaso L, Vogel A, Michalak S, Boursier J, Loménie N, Ziol M, Calderaro J. Zeng Q, et al. Among authors: inarrairaegui m. Lancet Oncol. 2023 Dec;24(12):1411-1422. doi: 10.1016/S1470-2045(23)00468-0. Epub 2023 Nov 8. Lancet Oncol. 2023. PMID: 37951222
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes.
Iñarrairaegui M, Melero I, Sangro B. Iñarrairaegui M, et al. Clin Cancer Res. 2018 Apr 1;24(7):1518-1524. doi: 10.1158/1078-0432.CCR-17-0289. Epub 2017 Nov 14. Clin Cancer Res. 2018. PMID: 29138342 Review.
Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation.
Rodríguez-Perálvarez M, Colmenero J, González A, Gastaca M, Curell A, Caballero-Marcos A, Sánchez-Martínez A, Di Maira T, Herrero JI, Almohalla C, Lorente S, Cuadrado-Lavín A, Pascual S, López-Garrido MÁ, González-Grande R, Gómez-Orellana A, Alejandre R, Zamora-Olaya J, Bernal-Bellido C; Chronic immunosuppression, cancer Spanish consortium. Rodríguez-Perálvarez M, et al. Am J Transplant. 2022 Jun;22(6):1671-1682. doi: 10.1111/ajt.17021. Epub 2022 Mar 31. Am J Transplant. 2022. PMID: 35286761 Free PMC article.
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L. Löffler MW, et al. Among authors: inarrairaegui m. Clin Cancer Res. 2022 Jun 13;28(12):2555-2566. doi: 10.1158/1078-0432.CCR-21-4424. Clin Cancer Res. 2022. PMID: 35421231 Clinical Trial.
Radioembolization for hepatocellular carcinoma.
Sangro B, Iñarrairaegui M, Bilbao JI. Sangro B, et al. Among authors: inarrairaegui m. J Hepatol. 2012 Feb;56(2):464-73. doi: 10.1016/j.jhep.2011.07.012. Epub 2011 Aug 2. J Hepatol. 2012. PMID: 21816126 Free article. Review.
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study.
de la Torre-Aláez M, Matilla A, Varela M, Iñarrairaegui M, Reig M, Lledó JL, Arenas JI, Lorente S, Testillano M, Márquez L, Da Fonseca L, Argemí J, Gómez-Martin C, Rodriguez-Fraile M, Bilbao JI, Sangro B. de la Torre-Aláez M, et al. Among authors: inarrairaegui m. J Immunother Cancer. 2022 Nov;10(11):e005457. doi: 10.1136/jitc-2022-005457. J Immunother Cancer. 2022. PMID: 36450386 Free PMC article. Clinical Trial.
Neoantigens as potential vaccines in hepatocellular carcinoma.
Repáraz D, Ruiz M, Llopiz D, Silva L, Vercher E, Aparicio B, Egea J, Tamayo-Uria I, Hervás-Stubbs S, García-Balduz J, Castro C, Iñarrairaegui M, Tagliamonte M, Mauriello A, Cavalluzzo B, Buonaguro L, Rohrer C, Heim K, Tauber C, Hofmann M, Thimme R, Sangro B, Sarobe P. Repáraz D, et al. Among authors: inarrairaegui m. J Immunother Cancer. 2022 Feb;10(2):e003978. doi: 10.1136/jitc-2021-003978. J Immunother Cancer. 2022. PMID: 35193931 Free PMC article.
95 results